NCT00077818已完成4 期
A Prospective, Open-label, Randomized, Parallel-group Investigation to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Sanofi
- 主要终点
- To assess a composite score that considers the occurrence of all-cause mortality, non-fatal MI, or recurrent angina requiring the need for revascularization
研究概览
简要总结
The purpose of this study is to determine the efficacy and safety of enoxaparin compared to unfractionated heparin (UFH) for patients diagnosed with Acute Coronary Syndrome (ACS) in the emergency department (ED). Efficacy is assessed by using a composite score consisting of 30-day all-cause mortality, non-fatal myocardial infarction (MI) and recurrent angina requiring revascularization.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Rest angina lasting at least 10 minutes that is highly suggestive of myocardial ischemia and is not explained by trauma or obvious abnormalities on chest x-ray, occurring within 24 hours of randomization;
- •TIMI risk score greater than or equal to 4 (a qualitative test for CK-MB or Troponin may be utilized for screening purposes; however, a quantitative test must still be performed.)
排除标准
- •Increased bleeding risk as defined by any of the following:
- •Ischemic stroke within the last year
- •Any previous hemorrhagic stroke, intracranial tumor, or intracranial aneurysm
- •Recent (<1 month) trauma or major surgery (including bypass surgery)
- •Active bleeding (other than minor skin abrasions)
- •Impaired hemostasis including any one of the following:
- •Known International Normalized Ratio (INR) >1.5
- •Past or present bleeding disorder (including congenital bleeding disorders such as von Willebrand's disease or hemophilia, acquired bleeding disorders, and unexplained clinically significant bleeding disorders)
- •Known or history of thrombocytopenia (platelet count <100,000/mL)
- •History of thrombocytopenia with glycoprotein IIb/IIIa inhibitor therapy, heparin, or enoxaparin
- •Angina from a secondary cause such as:
- •severe, uncontrolled hypertension (systolic blood pressure >180 mm Hg despite treatment)
- •valvular disease
- •congenital heart disease
- •hypertrophic cardiomyopathy
- •restrictive or constrictive cardiomyopathy
- •thyrotoxicosis.
- •Bundle branch block not known to be old in the context of angina.
- •Undergone a percutaneous coronary intervention (PCI) within the past 24 hours.
- •A known allergy to heparin, low molecular weight heparin, pork or pork products.
- •Any contraindications to treatment with UFH or LMWH.
- •A recent (<48 hours) or planned spinal/epidural anesthesia or puncture.
- •Thrombolytic therapy within the preceding 24 hours.
- •Any other clinically relevant serious diseases, including severe liver disease or renal failure [creatinine clearance <30 mL/min], rendering implementation of the protocol or interpretation of the study results difficult.
- •Treatment with other investigational agents or devices within the previous 30 days, planned use of investigational drugs or devices, or has previously enrolled in this trial.
- •Inability to comply with the protocol (e.g., has uncooperative attitude, inability to return for follow-up visits).
- •Inability to understand the nature, scope, and possible consequences of the study or is otherwise unable to provide informed consent.
- •A prosthetic heart valve
结局指标
主要结局
To assess a composite score that considers the occurrence of all-cause mortality, non-fatal MI, or recurrent angina requiring the need for revascularization
时间窗: up to 30 days (± 2 days) following randomization
次要结局
- Incidence of major hemorrhage(during the index hospitalization)
- Incidence of minor hemorrhage(during the index hospitalization)
- Combined incidence of 30-day all-cause mortality and nonfatal MI(at 30 days)
- The incidence of 30-day all-cause mortality by itself(At 30 days)
- Total health care utilization(from baseline (initial hospitalization) through the Day 30 follow-up visit.)
研究者
相似试验
终止
4 期
Ischemia Driven Enoxaparin Therapy in ACS Presenting as Low Risk (IDEAL)Unstable AnginaNCT00518245Canadian Heart Research Centre11
已完成
3 期
Safety and usefulness of Enoxaparin versus unfractionated heparin in patients with ST elevation myocardial infarctioIschaemic heart diseases.Acute myocardial infarctionIRCT138711271695N1Tehran University of Medical Sciences and Health Services150
已完成
3 期
Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)Acute ST-Segment ElevationMyocardial InfarctionNCT00077792Sanofi20,506
已完成
2 期
Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)Percutaneous Coronary InterventionNCT00077844Sanofi3,532
招募中
3 期
Enoxaparin in Treatment of Vascular Intra-Uterine Growth RetardatioIntra-uterine growth retardation.IRCT20180819040830N4Tehran University of Medical Sciences126